SCHEMBL19100815

SCHEMBL19100815

CC(Cn1cnc2c(NCc3ccccc3)ncnc21)OP(=O)(O)CP(=O)(O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ TMIGD3 P0DMS9 2/20 0.55
▸ ADORA2A P29274 2/20 0.55
▸ ADORA1 P30542 2/20 0.55
▸ CDK1 P06493 3/20 0.53
▸ CCNB2 O95067 2/20 0.53
▸ CCNB1 P14635 2/20 0.53
▸ CCNB3 Q8WWL7 2/20 0.53
▸ CDK2 P24941 1/20 0.53
▸ NT5E P21589 1/20 0.53
▸ NPC1 O15118 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.49
▸ IARS1 P41252 1/20 0.48
▸ DNPH1 O43598 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19100489 0.80 CDK1 (0.61) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL21348733 0.80 TMIGD3 (0.58) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL29539043 0.80 CDK1 (0.61) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL22843545 0.74 CDK1 (0.54) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL22571186 0.74 TMIGD3 (0.81) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL6901622 0.73 CDK1 (0.55) RAB9AKMT2AADORA2AADORA1CDK1
SCHEMBL6901637 0.73 CDK1 (0.55) RAB9AKMT2AADORA2AADORA1CDK1
SCHEMBL21450235 0.73 NT5E (0.54) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL27967736 0.73 RAB9A (0.70) RAB9AKMT2ATMIGD3ADORA2AADORA1
SCHEMBL27898315 0.73 CDK1 (0.59) RAB9AKMT2ATMIGD3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146059-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-05-28 — — US disclosed
US-12459967-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2025-11-04 — — US disclosed
US-20240352057-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2024-10-24 — — US disclosed
EP-4306525-A2 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF Arcus Biosciences, Inc. (US) 2024-01-17 — — EP disclosed
EP-3399984-B1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
EP-3399984-B1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
US-11667662-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2023-06-06 — — US disclosed
US-11667662-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2023-06-06 — — US disclosed
US-11667662-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2023-06-06 — — US disclosed
US-20210371449-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2021-12-02 — — US disclosed
US-20210002322-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2021-01-07 — — US disclosed
US-20190309010-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2019-10-10 — — US disclosed
US-20190309010-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2019-10-10 — — US disclosed
US-10239912-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2019-03-26 — — US disclosed
US-10239912-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ARCUS BIOSCIENCES, INC. (US) 2019-03-26 — — US disclosed
EP-3399984-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF Arcus Biosciences, Inc. (US) 2018-11-14 — — EP disclosed
US-20170267710-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2017-09-21 — — US disclosed
US-20170267710-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2017-09-21 — — US disclosed
US-20170267710-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. 2017-09-21 — — US disclosed
WO-2017120508-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2017-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240352057-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ENTPD5, NT5C2, NT5E RAB9A 1825/4885KMT2A 3759/4885TMIGD3 4016/4885
US-20210002322-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ENTPD5, NT5C2, NT5E RAB9A 1825/4885KMT2A 3759/4885TMIGD3 4016/4885
US-12459967-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ENTPD5, NT5C2, NT5E RAB9A 1848/4885KMT2A 3691/4885TMIGD3 3996/4885
US-20170267710-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ENTPD5, NT5C2, NT5E RAB9A 1825/4885KMT2A 3759/4885TMIGD3 4016/4885
US-20210371449-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ENTPD5, NT5C2, NT5E RAB9A 1825/4885KMT2A 3759/4885TMIGD3 4016/4885
US-20190309010-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF ENTPD5, NT5C2, NT5E RAB9A 1825/4885KMT2A 3759/4885TMIGD3 4016/4885
US-11667662-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ENTPD5, NT5C2, NT5E RAB9A 1848/4885KMT2A 3691/4885TMIGD3 3996/4885
US-10239912-B2 Modulators of 5′-nucleotidase, ecto and the use thereof ENTPD5, NT5C2, NT5E RAB9A 1848/4885KMT2A 3691/4885TMIGD3 3996/4885
US-20260146059-A1 MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF NTPCR, NT5C2, NT5E RAB9A 1742/4885KMT2A 4270/4885TMIGD3 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback